This HTML5 document contains 52 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/AHFS/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n14http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB08918/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/property/
n9http://linked.opendata.cz/resource/drugbank/drug/DB08918/identifier/kegg-drug/
n4http://linked.opendata.cz/resource/drugbank/drug/DB08918/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08918
rdf:type
n5:Drug
n5:description
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor. Chemically, levomilnacipran is the 1S,2R-enantiomer of milnacipran. FDA approved on July 25, 2013.
n5:dosage
n8:271B5D25-363D-11E5-9242-09173F13E4C5 n8:271B5D26-363D-11E5-9242-09173F13E4C5 n8:271B5D22-363D-11E5-9242-09173F13E4C5 n8:271B5D23-363D-11E5-9242-09173F13E4C5 n8:271B5D24-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# FDA label
n5:group
approved
n5:halfLife
12 hours
n5:indication
Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor and is indicated for the treatment of major depressive disorder (MDD).
owl:sameAs
n14:DB08918
dcterms:title
Levomilnacipran
adms:identifier
n4:DB08918 n9:D10072 n10:Levomilnacipran
n5:mechanismOfAction
The exact mechanism of the antidepressant action of levomilnacipran is unknown but is thought to be related to the potentiation of serotonin and norephinephrine in the central nervous system through inhibition of reuptake at serotonin and norepinephrine transporters.
n5:routeOfElimination
Levomilnacipran and its metabolites are eliminated primarily by renal excretion. 58% of the dose is excreted in urine as unchanged levomilnacipran. N-desethyl levomilnacipran is the major metabolite excreted in the urine and accounted for approximately 18% of the dose. Other identifiable metabolites excreted in the urine are levomilnacipran glucuronide (4%), desethyl-levomilnacipran glucuronide (3%), p-hydroxy levomilnacipran glucuronide (1%), and p-hydroxylevomilnacipran (1%). The metabolites are inactive.
n5:synonym
F-2695 Levomilnacipran
n5:toxicity
The most common adverse reactions are nausea, constipation, hyperhidrosis, heart rate increase, erectile dysfunction, tachycardia, vomiting, and palpitations.
n5:volumeOfDistribution
* 387 - 473 L [apparent volume of distribution]
n6:hasAHFSCode
n7:28-16-04-16
n5:proteinBinding
22% bound to human plasma protein over concentration range of 10 to 1000 ng/mL.
n5:salt
n5:IUPAC-Name
n11:271B5D28-363D-11E5-9242-09173F13E4C5
n5:InChI
n11:271B5D2E-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n11:271B5D2D-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n11:271B5D2A-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n11:271B5D2B-363D-11E5-9242-09173F13E4C5
n5:SMILES
n11:271B5D2C-363D-11E5-9242-09173F13E4C5
n5:logP
n11:271B5D27-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n11:271B5D34-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n11:271B5D35-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n11:271B5D2F-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n11:271B5D30-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n11:271B5D32-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n11:271B5D31-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n11:271B5D33-363D-11E5-9242-09173F13E4C5
n5:absorption
The relative bioavailability after administration of the extended-release capsule was 92% when compared to oral solution. Food does not affect the concentration of levomilnacipran. After daily dosing of levomilnacipran (extended-release capsule) the mean Cmax is 341 ng/mL, and the mean steady-state AUC value is 5196 ng·h/mL. The Tmax is 6 - 8 hours after oral administration. Interconversion of stereoisomers does not occur in humans.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
96847-55-1
n5:category
n5:clearance
* 21 - 29 L/h [mean apparent total clearance]
n5:Bioavailability
n11:271B5D39-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n11:271B5D3B-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n11:271B5D3C-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n11:271B5D38-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n11:271B5D37-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n11:271B5D3A-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n11:271B5D29-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n11:271B5D36-363D-11E5-9242-09173F13E4C5